期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
蒙成药阿木日-6临床与药理研究 被引量:9
1
作者 青格勒 朝鲁巴根 +3 位作者 巴特金 白玉亮 吴超群 白乌兰 《中国民族医药杂志》 2014年第3期47-48,共2页
蒙成药阿木日-6又名六味安消散,出自蒙医经典方剂学《至高要方》,由诃子、大黄、土木香、山柰、寒水石(煅)、碱花6味药物组成,是治疗消化系统疾病的常用蒙成药。1 蒙医传统用法本方性平,为不消化病的主方。方中大黄润肠,适用于... 蒙成药阿木日-6又名六味安消散,出自蒙医经典方剂学《至高要方》,由诃子、大黄、土木香、山柰、寒水石(煅)、碱花6味药物组成,是治疗消化系统疾病的常用蒙成药。1 蒙医传统用法本方性平,为不消化病的主方。方中大黄润肠,适用于大便秘结,胎盘滞留,中毒等症;光明盐以补胃火,消食,祛“巴达干”,适用于泛酸及大肠虫症;土木香具有清“巴达干”热、调气解郁、温胃消食、开欲、止刺痛的功效;山柰亦治积食不化,胃火衰退以及“巴达干”性哮喘。处方中诃子为君药,出自《本草图经》,为清凉解毒药,主治久泻、久痢、脱肛、喘咳痰嗽、久咳失音。大黄为臣药,主治实热便秘、热结胸痞、湿热泻痢、水肿腹满。全方性平五味相配,具有和胃健脾、导滞消积、行血止痛作用。适宜胃“巴达干”、胃“赫依”症[1],用以治疗未消化病、吐酸水、胃痛胀满、消化不良、便秘、痛经等症[2]。 展开更多
关键词 蒙成药 阿木日-6 适宜症 药理作用
下载PDF
Evaluation of the Appropriateness of Gastrointestinal Prophylaxis in the Critically III
2
作者 Kayla Torppey Leena Kansagra +1 位作者 Sheetal Patel Rouel Guiang 《Journal of Pharmacy and Pharmacology》 2016年第6期283-288,共6页
The aim of this study was to determine the utilization of SRMD (stress related mucosal disease) prophylaxis in the ICU (intensive care unit) of a large teaching institution based on duration and defined adverse ef... The aim of this study was to determine the utilization of SRMD (stress related mucosal disease) prophylaxis in the ICU (intensive care unit) of a large teaching institution based on duration and defined adverse effects. Patients were reviewed for appropriateness of SRMD prophylactic therapy based on the presence of two independent risk factors (coagulopathy and mechanical ventilation greater than 48 hours) versus presence of any one risk factor from a list developed by the study investigator. Data was collected into spreadsheets and outcomes were analyzed using descriptive statistics. When evaluating patients based on the presence of any risk factor, 84 percent of patients had at least one risk factor present, while 16 percent did not have any. In patients who received famotidine, there was one occtLrrence of Clostridium difficile and 6 cases of electrolyte abnormalities. In patients who received a PPI, there was one documented case of HAP, two cases of ventilator-associated pneumonia, three cases of Clostridium difficile, and 14 patients who developed electrolyte abnormalities. Data does not show an association between acid suppression therapy and incidence of nosocomial infections. The number of patients whose therapy exceeded the appropriate stop-date compared with the number of patients in which SRMD prophylaxis was discontinued when risk factors diminished was greater when evaluating patients based upon the two independent risk factors. 展开更多
关键词 Stress ulcer prophylaxis critical care GI prophylaxis proton pump inhibitor H2RA.
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部